GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal ...

GSK plc GSK reported adjusted earnings of 72 ... Sales of the influenza vaccine, Fluarix, were down 64% at CER. Sales of Established vaccines were up 8% year over year. Adjusted selling, general ...

The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...